NasdaqGM:ATAIPharmaceuticals
AtaiBeckley’s EMP-01 Data Strengthen Case For Psychedelic Anxiety Pipeline
AtaiBeckley reported detailed Phase 2a data for its oral R-MDMA candidate EMP-01 in adults with Social Anxiety Disorder.
The trial showed strong and consistent efficacy, with meaningful improvements in clinician- and patient-reported symptoms and real world behavioral outcomes.
EMP-01 was found to be safe and well tolerated, with high participant retention and no serious adverse events, and the results were achieved without adjunctive psychotherapy.
For AtaiBeckley, listed on NasdaqGM:ATAI,...